Purpose: To integrate the available data published to date on ameloblastic fibromas (AF) and ameloblastic fibrosarcomas (AFS) into a comprehensive analysis of their clinical/radiological features.
their clinical and radiological features, as well as the frequency of recurrence.
| MATERIALS AND METHODS
This study followed the PRISMA Statement guidelines. 6 
| Search strategies
An electronic search without time restrictions was undertaken and last updated in July 2017 in the following databases: PubMed/MED-LINE, Web of Science, Science Direct, J-Stage and LILACS. The following terms were used in the search strategies:
(ameloblastic fibroma) OR (ameloblastic fibrosarcoma) OR (ameloblastic sarcoma).
Google Scholar was also checked. A manual search of all related oral pathology, maxillofacial and specialist and oral journals was performed. The reference list of identified studies and the relevant reviews on the subject were also checked for possible additional studies. Publications with lesions identified by other authors as being AF or AFS, even not having the term "ameloblastic fibroma" or "ameloblastic fibrosarcoma" in the title of the article, were also reevaluated by an author (RSG) of this study.
| Inclusion and exclusion criteria
Eligibility criteria included publications reporting cases of AF or AFS.
The studies needed to contain enough clinical, radiological and histological information to confirm the diagnosis. The definitions and criteria of the World Health Classification of Tumors-Head and Neck Tumors book 1 (last updated in 2017) were used to diagnose the lesions. Randomized and controlled clinical trials, cohort studies, casecontrol studies, cross-sectional studies, case series and case reports were included. Exclusion criteria were immunohistochemical studies, histomorphometric studies, radiological studies, genetic expression studies, histopathological studies, cytological studies, cell proliferation/apoptosis studies, in vitro studies and review papers, unless any of these publication categories had reported any cases with enough clinical, radiological and histological information. Hybrid tumours containing parts of any of these lesions were not considered for this study, as they may behave differently from non-hybrid lesions. Ameloblastic sarcomatous lesions that presented hard tissue (ameloblastic fibrodentinosarcoma or ameloblastic fibro-odontosarcoma) were excluded. SD, standard deviation; AFS-primary, ameloblastic fibrosarcoma as primary lesion; AFS-secondary, ameloblastic fibrosarcoma occurring after an ameloblastic fibroma.
F I G U R E 1 Study screening process T A B L E 1 Demographic and clinical features of ameloblastic fibromas (AF) and ameloblastic fibrosarcomas (AFS) described in the literature

| Study selection
The titles and abstracts of all reports identified through the electronic searches were read independently by the authors. For studies appearing to meet the inclusion criteria, or for which there were insufficient data in the title and abstract to make a clear decision, the full report was obtained. Disagreements were solved by discussion between the authors. The clinical and radiological aspects, as well as the histological description of the lesions reported by the publications, were thoroughly assessed by one of the authors (RSG), an expert in oral pathology, to confirm the diagnosis of AF or AFS.
| Data extraction
The review authors independently extracted data using specially designed data extraction forms. Any disagreements were resolved by discussion. For each of the identified studies included, the following data were then extracted on a standard form, when available: year of publication, number of patients, patient's sex, age and race, fol- information on radiotherapy, chemotherapy, the number of recurrences, the occurrence of metastases and the patient's death were also collected. AFS were defined as "primary" or "secondary" depending on whether they were de novo lesions or occurred after an AF, respectively. The lesion size was determined according to the F I G U R E 2 Distribution of central ameloblastic fibromas (n = 279) according to age F I G U R E 3 Distribution of ameloblastic fibrosarcomas according to age (for the cases which the patients' age were informed, n = 102) F I G U R E 4 Topographical distribution of the known precise locations (n = 233) of central ameloblastic fibromas. Cases involving multiple regions (or an entire quadrant) are indicated between arrows. Numbers at the top and bottom of the lines indicate cases involving both adjoining regions: anterior/premolar, premolar/molar. The asterisk (*) indicates the number of lesions from the anterior mandible or mandibular body that reached the angle and/or ramus. For the rest of the lesions (n = 46), the location was the "maxilla" (n = 1), "anterior maxilla" (n = 1), "posterior maxilla" (n = 4), "right maxilla" (n = 1), "mandible" (n = 8), "anterior mandible" (n = 2), "posterior mandible" (n = 16), "anterior and posterior mandible" (n = 1), "mandibular body" (n = 4), "left mandible" (n = 1), "right mandible" (n = 1), "angle/ramus" (n = 1), "left ramus" (n = 1) and "first and second deciduous molars" (n = 1). The whole mandible was affected in 3 cases. The maxillary sinus was substantially affected in 16 lesions largest diameter reported in the publications. Contact with authors for possible missing data was performed.
| Analyses
The mean, standard deviation (SD) and percentages were presented as descriptive statistics. Kolmogorov-Smirnov test was performed to evaluate the normal distribution of the variables, and Levene's test evaluated homoscedasticity. The performed tests for two independent groups were Student's t test or Mann-Whitney test, depending on the normality. Pearson's chi-squared or Fisher's exact tests were used for categorical variables, depending on the expected count of events in a 2 9 2 contingency table. The probability of recurrence was calculated for several variables, in odds ratio (95% confidence interval). The degree of statistical significance was considered P < .05. All data were statistically analysed using the Statistical Package for the Social Sciences (SPSS) version 23 software (SPSS Inc., Chicago, IL, USA).
| RESULTS
| Literature search
The study selection process is summarized in Figure 1 Resection with continuity defect. AF, ameloblastic fibroma; AFS, ameloblastic fibrosarcoma, AFS, primary-ameloblastic fibrosarcoma as primary lesion; AFS-secondary, ameloblastic fibrosarcoma occurring after an ameloblastic fibroma. 
| Description of the studies and analyses
Two hundred and forty-four publications were included in the present review (Appendix S1). Table 1 Central AF and AFS were more prevalent in men than in women, and peripheral AF more prevalent in men. The mean age of the patients was higher in AFS than in central AF (P < .001). Table 2 ). Central AF recurred for the first time after 50.1 AE 55.6 months (mean AE SD, min-max, 6-228; n = 38). The mean AE SD time between the treatment of an AF and the occurrence of an AFS (secondary AFS) was 55.1 AE 54.7 (min-max, 3-168; n = 19). Larger lesions and older patients were more often treated by surgical resections for central AF (Table 3) .
Sixteen AFS patients died from complications related to the lesion (21.1% -information was available for 76 cases). Three of these patients refused further treatment after some recurrences.
There was information about the number of recurrences for 76 cases (considering recurrences for when an AFS was established-it does not consider the number of recurrences of AF, in case the AFS was secondary), of which 51 did not present recurrences (1 died), 7 subjects presented 1 recurrence (3 died), 9 individuals 2 recurrences (7 died), 3 patients 3 recurrences (2 died), 2 patients 4 recurrences
(1 died) and 1 patient each with 6 and 8 recurrences (both died). For 2 patients (1 with 1 recurrence, 1 with 2 recurrences), there was no information about death. Patients submitted to chemo-and radiotherapy had higher recurrence rates for AFS than those patients not submitted to the adjunctive therapies (Table 2) . AFS recurred for the first time after a mean AE SD of 22.2 AE 39.6 months (min-max, 2-168; n = 24). Nine and 20 patients (of 73) with AFS were submitted to chemotherapy and radiotherapy, respectively, as adjunctive therapy. Three variables were statistically significant different between primary and secondary AFS: mean age of the patient, presence of dislocated/unerupted teeth due to the lesion growth and the occurrence of metastases. Secondary AFS presented a higher recurrence rate than primary AFS (50% vs 28.8%), even though the difference did not present statistical significance. For the rest of the lesions (n = 33), the location was the "left maxilla" (n = 2), "posterior maxilla" (n = 3), "right maxilla" (n = 3), "left maxillary sinus" (n = 2), "mandible" (n = 1), "paramedian mandible" (n = 1), "posterior mandible" (n = 10), "right mandible" (n = 2), "left mandible" (n = 6), "left masticator space" (n = 1) and "middle face" (n = 1). The whole maxilla was affected in 1 case. For some of these 33 cases without precise location, the lesions' extension varied considerably, and some cases extended to the floor of the mouth, soft and hard palate, pterygoid fossa and medial/lateral muscles/ plates, epipharynx, nasopharynx, nasal cavity, nostril, ethmoidal bone, posterior ethmoidal cells, sphenoethmoid sinuses, sphenoidal bone, infratemporal fossa, temporalis muscle, orbit, orbital part of the frontal bone, forehead, epidular space, skull base, anterior/middle cranial fossae, cavernous sinus and basilar part of the occipital bone Table 6 shows the time of follow-up for different methods of 
| DISCUSSION
In the present literature review on AF and AFS, many publications were excluded because they did not meet the inclusion criteria. This is not to say that all of them were not AF or AFS, but suggests that the authors perhaps need to better describe their findings and that many reviews included cases that may have the diagnosis questioned.
Ameloblastic fibroma (AF) and AFS differed significantly with regard to bone expansion adjacent to the tumour, presence of clinical symptoms, cortical bone perforation, lesion mean size, mean age of the patients and recurrence rates.
Ameloblastic fibrosarcoma (AFS) more often presented as a multilocular radiolucency than central AF (52.3% vs 39.4%). As patients with AFS presented at a higher mean age when compared to those with AF, together with the fact that more than 50% of reported cases had histological documentation of AF in the same site, 7 it was hypothesized that there is a stepwise malignant transformation. 8 As AFS has an increased number and diversity of genetic alterations when compared to AF, 9 this stepwise malignant transformation may be associated with chromosomal instability. There were more cases of displaced/retained teeth by primary AFS than by secondary AFS.
This may be explained by the fact that many teeth were removed in surgery for AF. Therefore, fewer teeth are displaced or retained in the secondary AFS lesions.
Simple enucleation is related to a considerable recurrence rate for AF, a finding similar to that observed in keratocystic odontogenic tumours. 10 As about 25% of AFS develop in a recurrent AF, some believe that AF is more aggressive than previously thought and more radical treatment is needed. The trend observed by the results of our review suggests that more conservative approaches were used for AF in young patients, and surgical resections were more often considered in older patients and when the tumour is large. More radical surgery should also be considered when the tumour recurs more than once. 11, 12 Concerning the rate of secondary AFS observed here, the recurred and malignantly transformed cases of AF are more likely to be documented than ordinary cases in the form of case reports. 12 Therefore, it is possible that the rates of recurrence and malignant transformation found in our review are overestimated.
However, the vast majority (78.3%) of central AF cases were followed up up to 5 years. Malignant transformation of AF can occur An earlier diagnosis could reduce the risk of massive tumour extension resulting in devastating neurologic and cosmetic deformity. 14 The gradual disappearance of the epithelium component in some recurrent AFS has been used for tumour staging, but the few number of cases reported is an important limiting factor. Further studies are necessary to confirm whether a dominant epithelial component is a good prognostic sign. It is interesting to note a case described by Takeda et al. 17 noted several recurrences with increased malignancy and deposition of retinoid material, but the epithelial component remained. The patient died by direct invasion.
Patients with AFS treated with chemotherapy and/or radiotherapy as adjunctive therapy had a higher recurrence rate than those who did not have these treatments, although these modalities are more commonly used in aggressive cases. AFS treated by segmental resection had a 70.5% lower chance of recurrence when treated by marginal resection. Therefore, segmental resection is still the most recommended treatment for AFS.
The results of our study have to be interpreted with caution because of its limitations. First, all included studies were retrospective reports, which inherently result in errors, with incomplete records. Secondly, many of the published cases had a short followup, which could have led to an underestimation of the actual recurrence rate. However, it is hard to define what it would be considered a short follow-up period to evaluate the recurrence of these lesions. Thirdly, many of the cases described were published as isolated case reports or small case series.
| CONCLUSION S
Very long follow-up is recommended for AF lesions, due to the risk of recurrence or malignant transformation into AFS. Segmental resection is the most recommended therapy for AFS.
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